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Abstract
Background: A decrease in breast density due to tamoxifen preventive therapy might indicate greater benefit from
the drug. It is not known whether mammographic density continues to decline after 1 year of therapy, or whether
measures of breast density change are sufficiently stable for personalised recommendations.
Methods: Mammographic density was measured annually over up to 5 years in premenopausal women with no
previous diagnosis of breast cancer but at increased risk of breast cancer attending a family-history clinic in
Manchester, UK (baseline 2010-2013). Tamoxifen (20 mg/day) for prevention was prescribed for up to 5 years in one
group; the other group did not receive tamoxifen and were matched by age. Fully automatic methods were used on
mammograms over the 5-year follow-up: three area-based measures (NN-VAS, Stratus, Densitas) and one volumetric
(Volpara). Additionally, percentage breast density at baseline and first follow-up mammograms was measured visually.
The size of density declines at the first follow-up mammogram and thereafter was estimated using a linear mixed
model adjusted for age and body mass index. The stability of density change at 1 year was assessed by evaluating
mean squared error loss from predictions based on individual or mean density change at 1 year.
Results: Analysis used mammograms from 126 healthy premenopausal women before and as they received
tamoxifen for prevention (median age 42 years) and 172 matched controls (median age 41 years), with median 3 years
follow-up. There was a strong correlation between percentage density measures used on the same mammogram in
both the tamoxifen and no tamoxifen groups (all correlation coeficients > 0.8). Tamoxifen reduced mean breast
density in year 1 by approximately 17–25% of the inter-quartile range of four automated percentage density measures
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at baseline, and from year 2, it decreased further by approximately 2–7% per year. Predicting change at 2 years using
individual change at 1 year was approximately 60–300% worse than using mean change at 1year.
Conclusions: All measures showed a consistent and large average tamoxifen-induced change in density over the
first year, and a continued decline thereafter. However, these measures of density change at 1 year were not stable on
an individual basis.
Keywords: Tamoxifen, Prevention, Mammographic density, Breast density change
Introduction
Tamoxifen is used in adjuvant settings to reduce the
chance that breast cancer will reoccur when it has been
diagnosed at an early stage, and also to slow disease
progression in the advanced stage [1, 2]. It has been
licensed for breast cancer prevention in healthy women
at increased risk of the disease in several countries [3].
However, it might not be effective for prevention or treat-
ment of all women and it has certain harms, including a
slight increased risk of endometrial cancer, cataracts, pul-
monary embolism and deep vein thrombosis. It would be
useful to be able to better stratify women by risk in order
to determine who will benefit most from the drug.
In the treatment setting, several prognostic factors for
women diagnosed with breast cancer have been identified.
These include classical factors such as tumour size, grade
and lymph node involvement, and biomarkers including
Ki67 and commercial genetic signatures such as Onco-
typeDX, ProSigna and EpiClin [4]. In the prevention set-
ting, models are available to assess risk of breast cancer
and may be used to help target preventive therapy with
tamoxifen [5]. In both populations, there is evidence that
mammographic density reduction associated with tamox-
ifen is a further prognostic factor [6–14]. This biomarker
might help to personalise treatment and preventive ther-
apy, suggesting different management when no reduction
is seen. However, change in mammographic density asso-
ciated with endocrine therapy is not currently routinely
assessed nor incorporated into clinical decision-making.
An important gap in knowledge is how to measure
breast density change associated with tamoxifen. Reliabil-
ity is needed for baseline measurements to assess disease
risk or the need for use of additional screening modalities,
such as ultrasound, contrast-enhanced mammography or
magnetic resonance imaging (MRI). Reliability is some-
times measured by comparing measurement error with
the total variation in the sample (the ratio is equal to
1 minus the intra-class correlation coefficient). To help
determine the clinical utility of breast density change
associated with tamoxifen, we believe it is also impor-
tant to assess the stability of measures of individual breast
density change. Our definition of stability has not been
used previously to test measures of breast density change,
and so we introduce it next. It was developed following a
so-called predictive sequential (or prequential) approach
to inference [15]. This approach is more often applied
to compare competing forecasting models [16]. Here, we
test for lack of stability by determining whether using
observed density change for a woman at 1 year is a better
predictor of 2 years change than using the mean change
for all women at 1 year (i.e. same prediction for all). We
call anymeasure of density change that fails this predictive
test unstable. We find it to be a worthwhile test because
it would be hard to justify using an unstable measure of
breast density as a basis to recommend individual women
to stop therapy at 1 year.
The only study in the prevention setting to have shown
a relationship between density change and incidence of
breast cancer in healthy women receiving tamoxifen used
visual assessment on a 5% point scale by a single reader [7].
Other research studies on density change in the treatment
setting have also relied on visual assessment of breast den-
sity. In the adjuvant setting, this has been based on pairs
or sequences of mammograms approximately 1 year apart
[17–19]. In the tamoxifen-prevention setting, we are not
aware of reports with more than two measurements. As
most research has used visually assessed breast density
change between two time points, it might be considered
the current gold standardmethod. However, visual assess-
ment is impractical for routine use and not reliable due
to inter- and intra-reader variation and so more recent
work has considered fully automated measures of breast
density [20].
The main aim of this study was to determine the relia-
bility, stability and size of different measures of mammo-
graphic density change in premenopausal women receiv-
ing tamoxifen for preventive therapy, and in compari-
son with a group who did not receive tamoxifen. To
achieve this, we compared data from two cohorts of
high-risk women in Manchester, UK: (i) those enrolled
into a tamoxifen-prevention study (TAM-PREV) that was
designed to determine uptake of tamoxifen in the target
population and to investigate the possibility that we can
target treatment to women most likely to benefit, and (ii)
other women of the same age attending the same family-
history clinic, but without receiving tamoxifen over the
same period. Our objective was to assess average change
in different measures of breast density over 5 years, and to
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determine the reliability and stability of individual mam-
mographic density change in order to potentially guide
clinical decisions.
Methods
Patients
Premenopausal women with no previous diagnosis of
breast cancer and at high risk of breast cancer eligi-
ble for tamoxifen for prevention were invited to join the
TAM-PREV study, which was designed to study uptake
and acceptance of tamoxifen. Precise eligibility criteria
are given in the supplementary material. Participants in
TAM-PREV were given 20 mg/day of tamoxifen, orally
for a maximum 5 years. They attended yearly follow-
up appointments for mammography and where adher-
ence was monitored via self-report in person. Of the 135
women who joined TAM-PREV, n = 2 (1%) did not
receive tamoxifen; n=30 (22%) started but stopped tamox-
ifen within 1 year, a further n = 11 (8%), 17 (13%), 7 (5%)
and 3 (2%), respectively, in 1-year intervals from 1.5 to
4.5 years; and n = 76 (56%) completed the full 5 years.
A cohort consisting of women attending the same family-
history clinic who did not receive tamoxifen were also
enrolled and consented in the FH-Risk study. All partic-
ipants had a baseline mammogram over the same epoch
(2010–2013) [21].
Mammographic density
Full field digital mammography was used to screen
women for breast cancer at each visit. Both raw (DICOM
type ‘FOR PROCESSING’) and processed (‘FOR PRE-
SENTATION’) mammograms of two views (medio-lateral
oblique, MLO; cranial caudal, CC) of both breasts were
obtained and used to measure breast density by differ-
ent methods. The majority of mammograms were taken
using GE machines (80%); others were on Hologic, Ims
Giotto and Siemens Inspiration machines; in this analysis,
only GEmachines were used since one method (NN-VAS)
is only designed for mammograms from this manufac-
turer. Four fully objective measures of breast density were
computed on each of the images. They were (i) NN-VAS
(neural network fitted to percentage density on visual
assessment scale) version 1.0 [22], (ii) Volpara volumet-
ric density version 1.5.2 [23], (iii) Stratus [24] and (iv)
Densitas version 2.0.0 [20]. The mean of each density
measure over all views and both breasts was the single
measure used at each time point. Reliability of the differ-
ent density measures was broadly similar, with intra-class
correlation coefficients from 0.88 (Densitas) to 0.93 (Stra-
tus) (Supplementary Table S8). To enable comparisonwith
the results from the only study to show a relation to clini-
cal outcome [7] in the prevention setting, we included the
same visual percentage density change measure from that
study as a ‘gold standard’ reference. Percentage density
at baseline and first follow-up mammogram was deter-
mined visually by a single reader (RW). This was done
on a semi-continuous scale between 0 and 100% in 5%
increments, which is the same measure and expert reader
(RW) as an earlier study from the IBIS-I trial [7]. To assess
reproducibility, visual assessment was done on two sepa-
rate occasions: (i) when using both cohorts and blinded
to treatment allocation and order of mammograms, and
(ii) on a subset of the tamoxifen cohort and unblinded to
order of mammograms. This showed that visual assess-
ment of a 10% or more percentage change was discordant
for one quarter of those women assessed twice (26/100).
Study design
Up to two women in the no tamoxifen (control) group
were matched to the tamoxifen cohort (TAM-PREV),
based on availability of matched controls defined by age
at baseline mammogram (± 1 year) and year of baseline
mammogram. All women had a mammogram at entry to
the study (before tamoxifen use in the tamoxifen group)
and were seen annually in the family-history clinic for up
to 5 years for their routine follow-up appointment by AH
(median 3 years in both groups). For women in the tamox-
ifen group, only mammograms during active treatment
were used.
Statistical analysis
Change in percentage density was the primary mea-
sure and in comparison with visually assessed percent-
age density change. Change in dense area and volume
were assessed as secondary measures. The analysis only
included time points where all automated density mea-
sures were available. This was done to ensure valid com-
parisons between the measures. A similar proportion of
images were excluded for each method due to their inter-
nal quality control algorithms, except NN-VAS because
only GE mammograms could be run (total mammograms
n = 1798; exclusions: Volpara n = 72 (4%); Stratus
n = 124 (7%); Densitas n = 101 (6%); NN-VAS n = 387
(22%); total exclusions n = 450 (25%)). Analysis used sam-
ples of women with mammographic density available (A)
at baseline, (B) baseline and first year follow-up and (C)
the subset of (B) additionally with breast density at year 2
follow-up.
Summary statistics were reported on the original breast
density scale. All other analysis used transformed mea-
sures. Transformations were used to reduce skewness and
improve approximation to normality. Volumetric percent-
age density and dense volume were natural logarithm
transformed; percentage density measures square root
transformed. To helpmake comparisons between the den-
sity methods, the transformed densities were standard-
ised to have zero mean and unit inter-quartile range at
baseline. Correlation between the density methods was
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assessed between women through a weighted Pearson
correlation coefficient [25]. Cutpoints for density change
for automatedmethods were selected to aid interpretation
with respect to results from the IBIS-I trial [7]: density
change in automated methods was defined by a cutpoint
that yielded the same number of women in the no tamox-
ifen group above the cutpoint as the visual 10% absolute
density change method and cutpoint used in the earlier
study [7].
A normal linear mixed model for each density mea-
sure was fitted by maximum likelihood [26]. Fixed effects
were included for (1) intercept, (2) group (tamoxifen vs
no tamoxifen), (3) age (per 5 years), (4) body mass index
(per 5 kg/m2), (5) time greater than 1 year (indicator vari-
able), (6) year for year 2 onwards, (7) interaction between
terms (2) and (5) and (8) interaction between (2) and
(6). Random effects at the participant level were included
to allow for different trajectories for each woman for a
random intercept and slope (time since baseline mammo-
gram), which were assumed bivariate normal. The fixed
effects (5) and (7) allow for a different change in density
at 1 year between the groups; (6) and (8) allow for dif-
ferent rates of change by year thereafter. Missing body
mass index was imputed using the mean. Reliability was
estimated using intra-class correlation coefficients (ICCs)
from the model, being defined as the estimated resid-
ual variance divided by total variance. Profile likelihood
95% confidence intervals were obtained for the model
fit parameters. A non-parametric empirical bootrap 95%
confidence interval (3000 resamples) was used for the ICC
statistics. In a sensitivity analysis, the model was re-fitted
in the tamoxifen group alone (without fixed effects (2), (7)
and (8)).
A predictive test was used to assess stability of differ-
ent measures of breast density change at 1 year in women
receiving tamoxifen. This compared predicting change at
2 years to be either (i) individual change at 1 year or
(ii) mean density change at 1 year (i.e. the same pre-
dicted change in density for all women). Predictive ability
was measured using mean squared error (MSE). This loss
function is also the criterion used to fit ordinary linear
regression models. The MSE of (i) relative to reference (ii)
was estimated with non-parametric percentile bootstrap
95% confidence intervals.
All statistical analysis used software R 3.4.1 [27, 28]
Results
The two cohorts were broadly comparable at baseline in
analysis samples A (tamoxifen n = 126, no tamoxifen
n = 172), B (tamoxifen n = 94, no tamoxifen n =
112) and C (tamoxifen n = 70, no tamoxifen n = 89;
Fig. 1, Supplementary Tables S1-S5). The tamoxifen and
no tamoxien groups were well matched for age and had
similar body mass index. Approximately one quarter in
both the tamoxifen and no tamoxifen group were obese
(body mass index of greater than 30 kg/m2), one quarter
Fig. 1 Flow diagram with number of women showing the number of women included in analysis samples A (all women included in the study), B
(those with 1 year density change) and C (those with 1 year and 2 years density change measured)
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over weight (body mass index greater than 25 kg/m2), and
one quarter had a BMI less than approximately 22 kg/m2.
Projected lifetime risk was similar, with the majority at
high risk (more than 30% lifetime risk). Approximately
80% had children, and the age at first child was similar
in those with children, being 27 years on average in the
tamoxifen and no tamoxifen groups.
Mean percentage density differed substantially between
all methods of measurement, as did the average change
in percentage density between baseline and year 1 in
Table 1 Summary statistics of density measures at baseline (T0) and year 1 (T1) in analysis sample A (all women included in the study)
Tamoxifen No tamoxifen
N (unk%) Median (IQR, range) Mean (SD*) N (unk%) Median (IQR, range) Mean (SD)
Visual % blinded
Baseline 125 (1%) 25.0 (15.0–45.0, 0.0–90.0) 32.0 (21.7) 171 (1%) 30.0 (15.0–47.5, 0.0–80.0) 31.6 (20.6)
T1 98 (1%) 20.0 (10.0–40.0, 0.0–90.0) 26.0 (18.8) 122 (2%) 30.0 (15.0–50.0, 0.0–90.0) 33.5 (22.7)
T1–T0 94 (1%) −5.0 (−13.8–0.0, −45.0–20.0) −6.4 (9.8, −0.66) 112 (2%) 0.0 (−5.0–5.0, −25.0–30.0) −0.2 (9.6)
Visual % unblinded
Baseline 98 (22%) 25.0 (15.0–45.0, 0.0–95.0) 31.3 (20.5) 0 (100%)
T1 96 (3%) 20.0 (10.0–30.0, 0.0–90.0) 23.4 (18.0) 0 (100%)
T1–T0 92 (3%) −5.0 (−12.8–5.0, −35.0–25.0) −8.7 (9.4, −0.92) 0 (100%)
Stratus %
Baseline 126 (0%) 37.8 (13.5–56.8, 0.2–77.2) 34.6 (23.6) 172 (0%) 42.4 (9.1–58.0, 0.1–75.3) 36.2 (24.3)
T1 99 (0%) 27.6 (4.7–45.5, 0.1–67.4) 27.2 (21.3) 124 (0%) 42.7 (12.7–57.2, 0.1–71.0) 36.1 (23.5)
T1–T0 95 (0%) −6.2 (−12.9–0.9, −56.5–12.0) −7.8 (9.7, −0.81) 114 (0%) −0.1 (−3.5–1.5, −27.7–56.5) −0.2 (8.3)
Stratus DA
Baseline 126 (0%) 47.8 (17.2–64.7, 0.6–167.6) 46.5 (34.8) 172 (0%) 44.4 (16.9–67.3, 0.3–211.2) 48.3 (39.3)
T1 99 (0%) 29.9 (9.1–47.7, 0.2–128.1) 34.2 (28.9) 124 (0%) 42.2 (20.2–69.9, 0.3–181.5) 48.7 (38.5)
T1–T0 95 (0%) −10.8 (−19.2–3.3, −75.5–20.3) −13.0 (13.7, −0.95) 114 (0%) −1.0 (−6.3–3.2, −54.4–108.3) −0.5 (14.3)
Densitas %
Baseline 126 (0%) 41.0 (32.0–49.5, 12.0–73.0) 41.2 (12.9) 172 (0%) 42.0 (32.0–49.0, 10.0–72.0) 41.1 (12.3)
T1 99 (0%) 38.0 (29.0–47.0, 13.0–66.0) 37.7 (12.3) 124 (0%) 40.0 (34.0–50.2, 13.0–70.0) 41.4 (12.0)
T1–T0 95 (0%) −5.0 (−8.0–1.5, −21.0–34.0) −4.3 (7.0, −0.62) 114 (0%) 0.0 (−3.0–3.0, −21.0–25.0) −0.4 (5.9)
Densitas DA
Baseline 126 (0%) 44.0 (32.2–57.0, 15.0–131.0) 47.5 (22.3) 172 (0%) 41.5 (31.0–57.0, 19.0–162.0) 47.3 (24.0)
T1 99 (0%) 36.0 (27.5–49.5, 15.0–143.0) 41.4 (20.9) 124 (0%) 43.0 (33.0–55.2, 19.0–157.0) 48.5 (23.3)
T1–T0 95 (0%) −6.0 (−11.0–3.0, −35.0–103.0) −5.8 (14.0, -0.42) 114 (0%) 0.0 (−3.0–4.0, −42.0–33.0) 0.1 (8.2)
Volpara %
Baseline 126 (0%) 8.6 (5.4–15.7, 2.2–31.4) 11.0 (6.8) 172 (0%) 9.5 (5.7–14.1, 2.2–29.0) 10.7 (6.2)
T1 99 (0%) 7.5 (4.7–13.0, 2.1–27.8) 9.3 (5.8) 124 (0%) 9.1 (5.7–15.4, 2.1–28.2) 11.0 (6.2)
T1–T0 95 (0%) −0.9 (−2.3–0.2, −9.8–4.6) −1.4 (2.5, −0.56) 114 (0%) 0.0 (−0.9–0.9, −13.9–10.4) −0.2 (2.8)
Volpara DV
Baseline 126 (0%) 61.4 (43.9–86.2, 17.6–189.9) 69.4 (36.2) 172 (0%) 62.1 (40.6–89.1, 14.4–246.8) 70.7 (38.8)
T1 99 (0%) 49.7 (35.9–67.0, 17.5–173.1) 55.3 (27.3) 124 (0%) 57.5 (41.1–85.2, 11.3–196.5) 67.7 (38.4)
T1–T0 95 (0%) −11.0 (−21.6–2.7, −74.2–26.5) −14.2 (16.3, −0.87) 114 (0%) −2.5 (−11.3–4.5, −83.5–51.0) −3.8 (18.7)
NN-VAS %
Baseline 126 (0%) 41.1 (29.7–54.5, 7.1–76.8) 42.0 (16.3) 172 (0%) 43.8 (31.1–53.5, 8.4–76.0) 42.5 (16.1)
T1 99 (0%) 37.4 (23.6–47.0, 5.3–73.7) 36.9 (15.0) 124 (0%) 44.4 (31.2–54.2, 6.8–78.0) 42.5 (16.6)
T1–T0 95 (0%) −5.3 (−8.8–2.0, −24.2–18.1) −5.3 (5.8, −0.90) 114 (0%) −0.7 (−3.6–1.0, −19.8–31.8) −1.1 (6.0)
DA dense area, DV dense volume, IQR inter-quartile range, SD standard deviation, unk unknown
*T1–T0 for tamoxifen group statistic is mean (SD, mean/SD)
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the tamoxifen group. The mean absolute percent den-
sity change in women receiving tamoxifen ranged from
approximately 1.4 (Volpara) to 7.8% (Stratus), while there
was very little change during the first year in the no
tamoxifen group (Table 1). However, there was a strong
correlation between different percentage density mea-
sures in both the tamoxifen and no tamoxifen groups (all
repeated-measures correlation coefficient > 0.8, Table 2
and Supplementary Table S6, Supplementary Figure S1),
and on a standardised scale, the average change was sim-
ilar for different measures of breast density. Total volume
or area was negatively correlated with percentage density
partly because it is the denominator of percentage density.
Figure 2 shows an initial decline at 1 year followed by
a sustained decrease thereafter in the tamoxifen group.
This was also seen from age and BMI-adjusted estimates
of density change. The estimated adjusted change at 1 year
was approximately 17–25% of the IQR of each percent-
age density measure at baseline (Supplementary Table S7).
The adjusted yearly decrease in density from year 2 was
estimated to range from approximately 2 to 7% of IQR
change per year depending on the density measure. The
model fit was similar for each measure of breast density
(Supplementary Tables S7 and S8). In a model fitted to
the tamoxifen group alone, all methods except percentage
density by Densitas had a moderate correlation between
the random intercept and slope (approximately −0.3 to
−0.6, Supplementary Tables S9, S10), indicating a larger
tamoxifen-induced decrease in breast density for those
with higher breast density at baseline.
Results from automated methods of density change
were compared to visual assessment as the gold stan-
dard method. For a similar proportion of women who did
not receive tamoxifen (approximately 16%), the automated
methods identified a greater proportion of women in the
tamoxifen group with change above their high cutpoint
than visual assessment based on a 10% threshold (approx-
imately 60% for automated compared with 37% for visual;
Table 3). Of the 26 women with more than 10% den-
sity change based on visual assessment in the tamoxifen
group, n = 18 (Stratus and Volpara) to n = 20 (Densi-
tas and NN-VAS) were identified by automated methods.
The automatedmeasures all agreed on change at year 1 for
n = 19 (27%) of 70 women, but only 6 (9%) of 70 women
at first follow-up did not fall into a high change group by
any of the measures (Supplementary Table S11).
While similar average changes were detected, individual
breast density change at 1 year was not stable for 2 years
change using any measure. Predicting each woman’s den-
sity change at 2 years to be that observed at 1 year had
between approximately 60 to 300% greater error than
using the overall mean density change at 1 year (Table 4).
The lack of stability in measurement of individual breast
density change was further indicated by disagreement in
women above a threshold using the same density mea-
sure of change based on change at 1 year or 2 years for
approximately 40% women (Supplementary Table S12).
Discussion
This study investigated five measures of mammographic
density in women receiving tamoxifen preventive therapy,
compared with similar women who did not, over up to
5 years. The primary focus was on change at 1 year. There
were two main findings.
Firstly, all breast density measures revealed a large aver-
age change in density among women receiving tamoxifen
for prevention over the first year, and a continued average
decline thereafter. The size of these changes in compar-
ison with a no tamoxifen group was consistent between
the different measures when assessed on standardised
scales. This appears to be the first report in a preven-
tive setting to demonstrate there is a continued decline in
Table 2 Repeated measures correlation between density measures in the group of women that did not receive tamoxifen from
analysis sample A (all women included in the study)
Visual % Stratus % Densitas % Volpara % Stratus DA Densitas DA Volpara DV Densitas BA Volpara TV
Stratus % 0.85
Densitas % 0.87 0.90
Volpara % 0.89 0.92 0.92
Stratus DA 0.68 0.86 0.74 0.67
Densitas DA 0.12 0.14 0.18 −0.02 0.57
Volpara DV 0.40 0.41 0.44 0.28 0.73 0.81
Densitas BA −0.45 −0.48 −0.51 −0.62 −0.03 0.74 0.42
Volpara TV −0.49 −0.52 −0.49 −0.69 −0.05 0.64 0.50 0.88
NNVAS % 0.89 0.93 0.92 0.91 0.83 0.25 0.52 −0.39 −0.43
DA dense area, DV dense volume, BA breast area, TV total volume, NNVAS neural network visual assessment score
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Fig. 2Mean (standard error) standardised breast density at each time point from women a receiving tamoxifen and b not receiving tamoxifen,
using all women included in the study (analysis sample A). Standardised breast density uses transformed percentage density (natural logarithm for
Volpara, square root for others) that has been normalised to have mean zero and unit inter-quartile range at baseline
mammographic density beyond the first year of receiving
tamoxifen.
Secondly, even if breast density change over 1 year is a
prognostic or predictive biomarker for women receiving
tamoxifen for breast cancer prevention, current measures
of mammographic density might not measure change in
breast density at 1 year with sufficient stability for clini-
cal use. The analysis indicates that if a clinician advises a
woman that her breast density has changed by the amount
measured at 1 year, then on aggregate this may be up
to 300% worse (using mean squared error) as a predic-
tion of her 2 years breast density change than advising
all women that their density is likely to have changed
by the same amount. It therefore appears that mammo-
graphic density change at 1 year is not stable using current
technology.
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Table 3 Number of women with a decrease in breast density greater than a cutpoint using analysis sample C (women with density
change measured at 1 year and 2 years)
Cutpoint* Cutpoint* Tamoxifen No tamoxifen Decrease
Measure no change change No change Intermediate Decrease No change Intermediate Decrease difference (95% CI)
(a) Visual %
T1–T0 0.0 −10.0 24 (34%) 20 (29%) 26 (37%) 57 (64%) 18 (20%) 14 (16%) 21% (7–36%)
(b) Stratus %
T1–T0 0.0 −4.6 10 (14%) 16 (23%) 44 (63%) 45 (51%) 30 (34%) 14 (16%) 47% (32–62%)
T2–T0 0.0 −4.6 9 (13%) 14 (20%) 47 (67%) 50 (56%) 20 (22%) 19 (21%) 46% (31–61%)
(c) Densitas %
T1–T0 0.0 −3.6 9 (13%) 17 (24%) 44 (63%) 48 (54%) 27 (30%) 14 (16%) 47% (32–62%)
T2–T0 0.0 −3.6 7 (10%) 23 (33%) 40 (57%) 47 (53%) 24 (27%) 18 (20%) 37% (21–52%)
(d) Volpara %
T1–T0 0.0 −1.4 14 (20%) 17 (24%) 39 (56%) 45 (51%) 30 (34%) 14 (16%) 40% (25–55%)
T2–T0 0.0 −1.4 5 (7%) 19 (27%) 46 (66%) 48 (54%) 22 (25%) 19 (21%) 44% (29–60%)
(e) NNVAS %
T1–T0 0.0 −4.4 8 (11%) 24 (34%) 38 (54%) 36 (40%) 39 (44%) 14 (16%) 39% (23–54%)
T2–T0 0.0 −4.4 10 (14%) 14 (20%) 46 (66%) 47 (53%) 29 (33%) 13 (15%) 51% (37–66%)
T0, density at entry; T1, density at 1 year; T2, density at 2 year; no change, density change greater than or equal to this is classed as no change; change, density change less
than or equal to this is classed as decrease; the intermediate category is density in between these; decrease difference, absolute difference in density change percentage
between tamoxifen and no tamoxifen groups
*For automated methods, the cutpoints shown are for differences in transformed percentage density (×10), being the natural logarithm for Volpara and square root for the
other methods.
The standardised and transformed scales used alter
interpretation of the density change on the original scale.
The change in logarithm volumetric density is equivalent
to a relative change (ratio). The difference between square
root percentage density is less interpretable, but is partly
justified because on these transformed and standard-
ised scales all measures showed similar average effects of
tamoxifen through time, even though they are all different
algorithms. There were some apparent subtle differences,
such as Stratus showing a smaller decrease in standardised
density than the others (Fig. 2, Supplementary Table S7),
but we are cautious about over interpretation of such dif-
ferences. For example, we would observe a different point
estimate if we had applied a different transformation than
square root for Stratus (c.f. Supplementary Figure S1).
Overall results across the different density methods
were similar and in agreement with a gold standard
method based on visual assessment. The similar aver-
age effects and reliability (ICCs) suggest merit for all in
clinical studies designed to measure average change in
breast density. The similarity between methods is striking
because there are substantial differences between how the
algorithms function. The volumetric method (Volpara)
is based on a medical physics model. The other meth-
ods use machine learning algorithms. Stratus includes an
algorithm to align images so that density change is more
stable. NN-VAS was trained on visual assessment of raw
unprocessed images from the PROCAS study [22], which
was from the same Manchester setting as the present
study. Densitas uses processed DICOM files.
Despite agreement between measures on average, we
found that density change at an individual level was
not stable. This might be caused by other factors than
the breast density algorithms. Alternative explanations
include possible natural variation in breast density, such
as during the menstrual cycle. Another possible expla-
nation is variability in the way mammography might be
done through time. Further research could try to iden-
Table 4 Mean squared error (×100) in analysis sample C (women with density measured at 1 year and 2 years) {relative performance
(95% CI)} for predicting density change at 2 years, using mean density change at year 1 (REF = reference predictor) or individual
observed density change at year 1
Stratus % Densitas % Volpara % NNVAS%
Mean change T0–T1 6.0 {REF} 21.4 {REF} 4.2 {REF} 12.0 {REF}
Individual change T0–T1 14.5 {2.4 (1.6 to 3.3)} 65.9 {3.1 (1.8 to 3.9)} 10.0 {2.4 (1.8 to 3.0)} 19.7 {1.6 (1.3 to 2.3)}
T0 entry, T1 follow-up at 1 year
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tify how to make density change measures more stable.
The net result of this is that in settings that are similar to
the current study, it seems inappropriate to recommend
women to end tamoxifen after a year of use, solely on the
basis that their breast density has not decreased. Lack of
change at 1 year might be due to measurement error. On
the flip side, if a woman has observed a large breast den-
sity change at 1 year, then adherence could be encouraged
if findings from the single research study on breast den-
sity change and breast cancer incidence are replicated in
the future [7]. This is because they suggest that, on aver-
age, a group of women with larger density changes appear
to have better prognosis. Similar reasoning would apply in
a tamoxifen treatment context.
This study has a number of limitations. Firstly, due to the
study size, we were unable to link change in density due
to tamoxifen with subsequent risk reductions in breast
cancer. Secondly, treatment was not randomised between
the tamoxifen and no tamoxifen groups. Thirdly, we were
unable to assess what happened to breast density once
tamoxifen stopped being prescribed. Fourthly, weight and
menopausal status were not monitored through time for
all women. Knowing about these changes through time
would enable a more precise determination of breast den-
sity change since they are established to be associated with
breast density.
Strengths of this study include that compliance was
actively monitored yearly, and we excluded breast density
after drug use ended. This ensured an accurate measure
of the effect of tamoxifen on mammographic density, but
is also important for prognosis studies of breast den-
sity change. For example, a potential bias in studies of
breast density change and prognosis in women who have
been recommended to receive tamoxifen is that it could
partly reflect compliance: those who benefit are those who
received the drug.
In summary, on the aggregate level (e.g. evaluating an
entire population or clinical trial), tamoxifen-associated
density declines may provide an important signal (e.g. for
indicating tamoxifen effectiveness) but this signal appears
to be ‘too noisy’ at the individual level to use it to
make clinical recommendations. We expect these findings
would be generalisable to treatment settings as well, but
further studies are warranted to test this hypothesis.
Conclusions
Our study provides the first analysis in a tamoxifen-
prevention setting of longitudinal breast density mea-
sured yearly over up to 5 years, and includes fully auto-
mated measures that have not previously been exam-
ined in a tamoxifen prevention or treatment context.
The data provide important information on the relia-
bility, stability and size of breast density changes from
different methods used to measure breast density. All
measures showed a large average decline in breast den-
sity after 1 year of tamoxifen, and a continued decline in
mammographic density beyond the first year of receiv-
ing tamoxifen. All methods had relatively high intra-
class correlation coefficients (approximately 0.9) indicat-
ing a good degree of reliability. However, breast density
change at 1 year did not appear to be sufficiently sta-
ble to inform personalisation of clinical decisions on
the basis of a woman’s observed breast density change.
These findings will be important to clinicians and their
patients undergoing or considering endocrine therapy,
as well as regulators and ethics boards considering tri-
als of products that require information on the reliability
and stability of mammographic density reductions as an
endpoint.
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